Mandiri Jaya Medika is primarily engaged in pharmaceuticals activity. Its headquarters is located in Dki Jakarta. The company was founded in 2008. Mandiri Jaya Medika was founded by Dr. Rina Santoso and Mr. Agus Pratama, who envisioned creating a leading pharmaceutical company in Indonesia. The company focuses on the development, manufacturing, and distribution of a wide range of pharmaceutical products, including prescription medications, over-the-counter drugs, and health supplements. Mandiri Jaya Medika operates several branches across Indonesia, with a strong presence in major cities such as Surabaya, Bandung, and Medan. The company has also expanded its operations to neighboring countries in Southeast Asia, including Malaysia and Singapore, to cater to a broader market. The company's main product lines include cardiovascular drugs, antibiotics, and vitamins, marketed under well-known brand names such as CardioCare, BioAntibiotics, and VitaHealth. Mandiri Jaya Medika is committed to innovation and quality, ensuring that its products meet international standards. In collaboration with global pharmaceutical giants, Mandiri Jaya Medika has established joint ventures to enhance its research and development capabilities. The company is a member of the Indonesian Pharmaceutical Association and actively participates in industry events and forums. Mandiri Jaya Medika aims to improve public health by providing affordable and effective healthcare solutions. The company's mission is to become a trusted partner in healthcare, driven by a vision to enhance the quality of life for communities across the region.
Headquarters
B20
South Jakarta; Jakarta;
Postal Code: 12150
Contact Details: Purchase the PT Mandiri Jaya Medika report to view the information.
Website: http://www.mandirijayamedika.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service